Hypersensitivity to chemotherapeutic drugs for the treatment of neoplasms. Literature review
Open Access
- 18 December 2024
- journal article
- Published by Communicable Diseases Intensive Care Association in Infusion & Chemotherapy
- No. 4
Abstract
BACKGROUND. Like any other drug, chemotherapy drugs can cause hypersensitivity reactions and are the third leading cause of drug-induced anaphylaxis deaths in the United States. Timely detection of hypersensitivity reactions to chemotherapeutic drugs in oncology is extremely important because, unlike other drugs (for example, antibiotics or anesthetics), which can be relatively easily replaced by others, chemotherapeutic drugs are often unique and indispensable for the treatment of neoplasms. In such situations, the doctor should evaluate the benefits of continuing treatment in comparison with the risk of a potentially fatal anaphylactic reaction when continuing chemotherapy with the drug that caused the development of hypersensitivity reactions, and also look for the possibility of replacing the chemotherapeutic drug that has become an allergen with another one. OBJECTIVE. Analysis of existing data on the etiology, pathogenesis, clinic, diagnosis and prevention of hypersensitivity reactions associated with chemotherapy drugs for the treatment of neoplasms. MATERIALS AND METHODS. Search for available sources of information, their analytical processing and discussion of the obtained results. RESULTS. To date, there is a lack of data and research on approaches to the diagnosis and treatment of patients with neoplasms and hypersensitivity reactions to chemotherapy drugs. Cases of hypersensitivity reactions to chemotherapeutic drugs require the creation of a multidisciplinary team consisting of allergists, oncologists and therapists to choose rational tactics for managing such patients. For the diagnosis of hypersensitivity reactions to chemotherapeutic drugs, the clinical and anamnestic method, skin, laboratory and, if necessary, provocation tests with drugs should be used. Inorder to treat and prevent the development of hypersensitivity reactions to chemotherapeutic drugs, premedication with corticosteroids and antihistamines, replacement of the allergen drug, and in case of impossibility of such replacement, desensitization with the allergen drug should be used. CONCLUSIONS. The problem of the development of hypersensitivity reactions to chemotherapeutic drugs used for the treatment of patients with neoplasms is extremely important and requires further research.Keywords
This publication has 80 references indexed in Scilit:
- Importance of Diagnostics Prior to Desensitization in New Drug Hypersensitivity: Chemotherapeutics and BiologicalsCurrent Treatment Options in Allergy, 2020
- Pain descriptors of taxane acute pain syndrome (TAPS) in breast cancer patients—a prospective clinical studySupportive Care in Cancer, 2019
- Methotrexate hypersensitivity reactions in pediatrics: Evaluation and managementPediatric Blood & Cancer, 2016
- Comparison of hypersensitivity rates to intravenous and intramuscular PEG‐asparaginase in children with acute lymphoblastic leukemia: A meta‐analysis and systematic reviewPediatric Blood & Cancer, 2016
- Presentation and Diagnosis of Hypersensitivity to Platinum DrugsCurrent Allergy and Asthma Reports, 2015
- Drug-induced anaphylaxis: a decade review of reporting to the Portuguese Pharmacovigilance AuthorityEuropean Journal of Clinical Pharmacology, 2012
- Cross-sensitivity between taxanes in patients with breast cancerClinical and Translational Oncology, 2011
- Rapid IgE desensitization is antigen specific and impairs early and late mast cell responses targeting FcεRI internalizationEuropean Journal of Immunology, 2011
- Hypersensitivity reactions to oxaliplatin and other antineoplastic agentsCurrent Allergy and Asthma Reports, 2008
- Analysis of Patients with Epithelial Ovarian Cancer or Fallopian Tube Carcinoma Retreated with Cisplatin after the Development of a Carboplatin AllergyGynecologic Oncology, 2002